Research Analysts Offer Predictions for Precision BioSciences, Inc.’s Q2 2022 Earnings (NASDAQ:DTIL)

Precision BioSciences, Inc. (NASDAQ:DTIL – Get Rating) – Equities researchers at William Blair raised their Q2 2022 EPS estimates for shares of Precision BioSciences in a research note issued on Monday, May 9th. William Blair analyst R. Prasad now forecasts that the company will post earnings per share of ($0.44) for the quarter, up from their prior estimate of ($0.51). William Blair also issued estimates for Precision BioSciences’ Q3 2022 earnings at ($0.45) EPS, Q4 2022 earnings at ($0.46) EPS, FY2022 earnings at ($1.80) EPS, Q1 2023 earnings at ($0.47) EPS, Q2 2023 earnings at ($0.47) EPS, Q3 2023 earnings at ($0.48) EPS, Q4 2023 earnings at ($0.48) EPS and FY2023 earnings at ($1.89) EPS.

Several other analysts also recently weighed in on DTIL. The Goldman Sachs Group reduced their target price on Precision BioSciences from $12.00 to $5.00 and set a “neutral” rating for the company in a report on Wednesday, March 16th. Zacks Investment Research downgraded shares of Precision BioSciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 19th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $16.60.

NASDAQ:DTIL opened at $1.65 on Thursday. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.50 and a quick ratio of 4.50. Precision BioSciences has a 12 month low of $1.64 and a 12 month high of $14.38. The firm has a market capitalization of $100.71 million, a PE ratio of -3.06 and a beta of 1.82. The business’s fifty day moving average price is $2.85 and its 200 day moving average price is $5.66.

Precision BioSciences (NASDAQ:DTIL – Get Rating) last posted its quarterly earnings data on Tuesday, March 15th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.10. Precision BioSciences had a negative net margin of 26.49% and a negative return on equity of 34.78%. The business had revenue of $6.34 million during the quarter, compared to analyst estimates of $8.24 million.

In other news, CFO John Alexander Kelly bought 16,677 shares of the firm’s stock in a transaction dated Thursday, March 17th. The stock was acquired at an average cost of $3.08 per share, for a total transaction of $51,365.16. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 8.50% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Macquarie Group Ltd. bought a new position in Precision BioSciences during the third quarter worth $55,000. Denali Advisors LLC acquired a new stake in shares of Precision BioSciences during the fourth quarter worth $48,000. O Shaughnessy Asset Management LLC bought a new position in shares of Precision BioSciences in the 3rd quarter worth about $81,000. Ensign Peak Advisors Inc bought a new position in shares of Precision BioSciences in the 4th quarter worth about $73,000. Finally, Commonwealth Equity Services LLC acquired a new position in Precision BioSciences in the first quarter valued at approximately $31,000. Institutional investors and hedge funds own 51.65% of the company’s stock.

About Precision BioSciences (Get Rating)

Precision BioSciences, Inc, a clinical stage gene editing company, develops vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which a specific type of immune cell, called a T cell, is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma.

Featured Articles